Ready in 24 Hours: ATreg Featured in Labiotech’s GvHD Pipeline Review!
The GvHD field is shifting from treating established disease toward preventing it by restoring immune tolerance. Labiotech’s new overview of the 2026 GvHD pipeline maps this transition and features ActiTrexx and our ATreg/actileucel (ATX-002) program among the most promising candidates in clinical development.
Our approach uses regulatory T cells from healthy, unrelated donors, activated in just 16 hours and ready for administration within 24 hours. There is no weeks-long expansion and no HLA matching. In the world’s first clinical trial with activated Tregs, ATreg proved feasible, safe and well tolerated for the prevention of acute GvHD.
Read the full article: Labiotech’s GvHD Pipeline Overview 2026